These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 34292643

  • 1. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Ozanimod Study Investigators.
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 4. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA.
    Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
    [Abstract] [Full Text] [Related]

  • 5. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Kuhle J, Chitnis T, Banwell B, Tardieu M, Arnold DL, Rawlings AM, Geertsen SS, Lublin AL, Saubadu S, Truffinet P, Kappos L.
    Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
    [Abstract] [Full Text] [Related]

  • 6. Phase III SUNBEAM and RADIANCE PART B trials for Ozanimod in relapsing multiple sclerosis demonstrate superiority versus interferon-β-1a (Avonex®) in reducing annualized relapse rates and MRI brain lesions.
    Koscielny V.
    Neurodegener Dis Manag; 2018 Jun; 8(3):141-142. PubMed ID: 29943693
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons.
    Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.
    J Comp Eff Res; 2024 Oct; 13(10):e230161. PubMed ID: 39158844
    [Abstract] [Full Text] [Related]

  • 8. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D, Kropshofer H, Häring DA, Dahlke F, Patil A, Meinert R, Tomic D, Kappos L, Kuhle J.
    Neurology; 2022 May 24; 98(21):e2120-e2131. PubMed ID: 35379762
    [Abstract] [Full Text] [Related]

  • 9. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul 24; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug 24; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 11. Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients.
    Szilasiová J, Rosenberger J, Fedičová M, Mikula P, Urban P, Gdovinová Z, Vitková M, Hanes J, Stevens E.
    Eur Neurol; 2021 Aug 24; 84(4):272-279. PubMed ID: 34034261
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr 24; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 13. Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.
    Cohan S, Tencer T, Arndorfer S, Zhu X, Zivkovic M, Kumar J.
    Mult Scler Relat Disord; 2021 Jul 24; 52():102972. PubMed ID: 33979770
    [Abstract] [Full Text] [Related]

  • 14. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun 24; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 15. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P, Vestenická V, Siarnik P, Sivakova M, Čopíková-Cudráková D, Belan V, Hanes J, Novák M, Kollar B, Turcani P.
    Neuro Endocrinol Lett; 2020 Apr 24; 41(1):17-26. PubMed ID: 32338853
    [Abstract] [Full Text] [Related]

  • 16. Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis.
    Szilasiova J, Mikula P, Rosenberger J, Fedicova M, Urban P, Frigova L, Vitkova M, Gdovinova Z, Hanes J, Stevens E.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Sep 24; 166(3):304-311. PubMed ID: 34092793
    [Abstract] [Full Text] [Related]

  • 17. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL.
    Neurology; 2019 Nov 05; 93(19):e1778-e1786. PubMed ID: 31484710
    [Abstract] [Full Text] [Related]

  • 18. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov 05; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 19. Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
    Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, Leppert D, Tsai JA, Plavina T, Kieseier BC, Lycke J, Alfredsson L, Kockum I, Kuhle J, Olsson T, Piehl F.
    Neurology; 2020 Mar 17; 94(11):e1201-e1212. PubMed ID: 32047070
    [Abstract] [Full Text] [Related]

  • 20. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A.
    BMC Neurol; 2018 Sep 14; 18(1):143. PubMed ID: 30217172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.